Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts

Richard Balasubramaniam1, Sangeeta Chawla, Lauren Mackenzie

  • 1Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG, United Kingdom. rnb25@cam.ac.uk

Insights

Beta-adrenergic stimulation triggers ventricular arrhythmias in mouse hearts. L-type calcium channel blockers like nifedipine and diltiazem effectively suppress these arrhythmias and normalize calcium handling.

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Electrophysiology
  • Pharmacology

Background:

  • Ventricular arrhythmias and sudden cardiac death are major concerns in heart failure and long-QT syndrome (LQTS).
  • Beta-adrenergic stimulation can exacerbate these arrhythmias.
  • L-type calcium channel blockers are used clinically, but their role in modulating beta-adrenergic-driven arrhythmias needs further elucidation.

Purpose of the Study:

  • To investigate the effects of beta-adrenergic stimulation and L-type calcium channel blockade on ventricular arrhythmogenesis.
  • To examine the impact on intracellular calcium handling in mouse ventricular myocytes.

Main Methods:

  • Langendorff-perfused mouse hearts subjected to programmed electrical stimulation.
  • Confocal microscopy of fluo-3 loaded ventricular myocytes to assess sarcoplasmic reticulum calcium release.
  • Pharmacological interventions included isoprenaline, nifedipine, and diltiazem.

Main Results:

  • Isoprenaline induced sustained ventricular tachycardia, which was abolished by nifedipine or diltiazem.
  • Isoprenaline increased sarcoplasmic reticulum calcium release, an effect normalized by L-type calcium channel blockers.
  • Elevated external calcium also induced arrhythmias and increased calcium release.

Conclusions:

  • Beta-adrenergic stimulation promotes ventricular arrhythmias through enhanced calcium release.
  • L-type calcium channel blockade effectively suppresses these arrhythmias and normalizes calcium handling.
  • Findings suggest a potential therapeutic role for L-type calcium channel blockers in managing beta-adrenergically driven ventricular arrhythmias.